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harmacological Facilitation
f Coronary Intervention in
T-Segment Elevation
yocardial Infarction
ime Is of the Essence*
ernard J. Gersh, MB, CHB, DPHIL,†
regg W. Stone, MD‡
ochester, Minnesota; and New York, New York
he dawn of the reperfusion era more than 3 decades ago
evolutionized the management of ST-segment elevation
yocardial infarction (STEMI). Over the years, reperfusion
herapy has matured, a consequence of numerous trials that
ave defined the optimal class of fibrinolytic drugs (fibrin-
pecific agents), the timing of therapy, adjunctive anti-
hrombotic and antiplatelet medication, and the role of
rimary percutaneous coronary intervention (PPCI). Spe-
ifically, the introduction and globalization of PPCI has
esulted in another sea change in STEMI management as
andomized controlled trials have clearly demonstrated the
uperiority of PPCI to fibrinolysis, provided that PPCI can
e delivered in a timely fashion (1). Nonetheless, important
See page 1284
uestions remain unanswered. First, in patients presenting
elatively early (within 2 to 3 h of symptoms to a hospital
ithout PCI capabilities), what is the acceptable duration of
elay for transport for PPCI as opposed to administration of
mmediate fibrinolytic therapy? Second, what therapies
hould be administered before and during transport (e.g., an
ntithrombin agent such as heparin or bivalirudin with a
hienopyridine or a glycoprotein IIb/IIIa inhibitor)? Specif-
cally, should fibrinolytic therapy be given immediately
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edispec, and Boston Scientific.efore transfer followed by routine emergency angiography
nd PCI upon arrival at the tertiary hospital (facilitated
CI)? Third, despite considerable progress, the prompt
elivery of reperfusion therapy to all eligible patients does
ot always occur. Finally, the discordance between the high
uccess rate of infarct artery recanalization currently
chieved by PCI and the lack of effective myocardial
erfusion and recovery in many patients remains an area of
nvestigation, with discouraging results to date (2).
The present FINESSE (Facilitated Intervention With
nhanced Reperfusion Speed to Stop Events) substudy (3)
ublished in this issue of JACC: Cardiovascular Interventions
ouches on several these unanswered issues. The FINESSE
tudy was a large randomized trial designed to evaluate the
ffects and clinical outcomes at 90 days of 2 strategies,
amely the immediate administration of abciximab alone or
n conjunction with half-dose reteplase before “routine
mmediate” PCI (facilitated PCI) versus primary PCI with
bciximab administered for the first time in the catheter-
zation laboratory (4). The trial was neutral with no signif-
cant reduction in the 90-day primary ischemic end point in
he facilitated PCI group. The present angiographic sub-
tudy (FINESSE-ANGIO) enrolled 637 of the total 2,452
atients from 6 countries in Europe. The primary substudy
nd point was infarct-related artery (IRA) patency (Throm-
olysis In Myocardial Infarction [TIMI] flow grade 2/3) at
asal coronary angiography; secondary efficacy end points
ere the corrected TIMI frame count, the percentage of
atients achieving TIMI flow grade 3, and myocardial blush
rade 2/3 after PCI—the latter being a surrogate for
yocardial perfusion and presumably microvascular dys-
unction. With a median time from drug administration to
rst angiography of 55 min, baseline IRA patency in the
ombination-facilitated PCI group was higher than with
bciximab alone before treatment or placebo before PPCI
76.1% vs. 43.7% vs. 32.7%, respectively), but post-PCI mea-
ures of epicardial coronary flow and myocardial perfusion were
imilar between the groups. Nor did this early angiographic
enefit translate into any improvement in clinical outcomes.
re these results paradoxical or an expected consequence of
hat we know or assume about the relationship between time
o reperfusion and its impact upon arterial patency, myocardial
alvage, and clinical outcomes?
Figure 1 is a hypothetical construct of the relationship
etween time to reperfusion, the extent of myocardial
alvage, and reduction in mortality (5). Modifying factors
nclude the presence of collaterals, myocardial oxygen de-
and, perhaps ischemic pre-conditioning, and other un-
dentified variables. Clinical trials in which infarct size was
easured with sestamibi imaging support the “slope of the
urve” concept by illustrating a narrow window for myocar-
ial salvage within the first 1 to 3 h following symptom
nset, followed by a “flat portion of the curve” during which
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1293ere to shorten the PCI-related delay time by achieving
IMI flow grade 3 30 to 60 min earlier, this should
ogically increase myocardial salvage and, depending
pon the magnitude of the extent of ischemic myocardial
eopardy, could result in improved clinical outcomes. The
bility to achieve incremental myocardial salvage, how-
ver, is critically dependent upon the total duration of
schemia not yet reaching the flat portion of the curve
efore reperfusion. Unfortunately, as previously discussed
egarding the negative ASSENT 4 (Assessment of the
afety and Efficacy of a New Treatment Strategy for
cute Myocardial Infarction) trial (7), considering the
pproximate 2-h median delay from symptom onset to
ospital arrival in the U.S and many other countries, the 30
o 60 min that lytics require for stable reperfusion, and the
act that door-to-balloon times are now routinely 90 min,
eperfusion with fibrinolytic agents would be unlikely to
ccur much before the expected time of PCI. Moreover, this
orresponds to a point on the curve in which incremental
ffects on myocardial salvage are unlikely. In the FINESSE-
NGIO trial, the median time from the qualifying electro-
ardiogram to drug administration was 41 min, and the
edian time from symptom onset to the start of any
eperfusion therapy was 3.5 h, which already places most
atients on the “flat” part of the curve, at which time earlier
ttainment of TIMI flow grade 3 is unlikely to provide
ncremental myocardial salvage compared with PPCI alone.
In contrast to FINESSE and ASSENT 4, prior series (8)
ave demonstrated that the presence of TIMI flow grade 3
efore PPCI is associated with improved survival. In these
Figure 1. Relationship Between Mortality Reduction and Extent
of Salvage
Postulated relationship between duration of ischemia before reperfusion,
extent of myocardial salvage, mortality reduction, and goals of therapy.
Reprinted, with permission, from Opie L, Gersh BJ, editors. Drugs for the
Heart, 7th ed.. Philadelphia: Elsevier/W. B. Saunders, 2009. IRA  infarct-
related artery; MVO2  myocardial oxygen consumption; PCI  percutane-
ous coronary intervention.tudies, TIMI flow grade 3 occurred due to spontaneous ohrombus resolution (or persistent subtotal occlusion), and
ndeed may reflect restoration of patency much earlier after
ymptom onset in contrast to the FINESSE-ANGIO
tudy. Moreover, with facilitated PCI (as opposed to spon-
aneous IRA recanalization), the deleterious effects of
brinolysis-mediated early reperfusion including platelet
ctivation (resulting in IRA reocclusion or recurrent isch-
mia), and hemorrhagic complications (such as intracranial
nd intramyocardial hemorrhage) cannot be discounted, and
ay more than offset any beneficial effects of early vessel
atency. This may explain why harm has been demonstrated
ith pharmacological facilitation in numerous trials (9).
The concept of pharmacological facilitation remains log-
cal (if unproven), particularly in high-risk STEMI patients
e.g., anterior MI) who present early to a non-PCI center
nd in a setting in which transport-related delays are lengthy
10). Ideally, randomized controlled trials would be per-
ormed to determine the exact conditions under which
acilitation would provide superior outcomes to PPCI alone
with only aspirin, a potent thienopyridine, and an anti-
hrombin agent provided before transport). A remaining
ssue is whether a facilitated approach that mandates “rou-
ine immediate PCI” is as safe and more effective than the
revailing concept of a “pharmacoinvasive strategy,” in
hich fibrinolytic therapy is followed by rescue PCI in
nstable patients or in those with ongoing chest pain or
T-segment elevation, or by routine but delayed angiogra-
hy with PCI as appropriate within 3 to 24 h in stable
atients. Timing and appropriate patient selection is of the
ssence, however, because even the subgroup of patients in
he large ASSENT 4 trial assigned to pharmacological
acilitation within 2 h of symptom onset experienced no
lear benefits.
Another aspect raised by the FINESSE-ANGIO study is
he discordance between IRA recanalization and measures
f myocardial perfusion and microvascular function. Al-
hough cardiac magnetic resonance imaging may currently
e the best method for measuring the extent of left
entricular scar, microvascular dysfunction, and the poten-
ial for late myocardial recovery, myocardial blush grade and
T-segment resolution are reasonable surrogates and pro-
ide incremental predictive information (11). Studies using
hese indexes of myocardial perfusion highlight the fact that
chieving normal epicardial coronary blood flow does not
nsure normalized myocardial perfusion, microvascular
unction, and metabolism. Despite the demonstrated exper-
mental efficacy of numerous cardioprotective agents and
trategies in mice and other animal models, clinical trials in
umans for the most part have been disappointing (2).
erhaps this relates in part to a fundamental lack of
nderstanding of the basic mechanisms of reperfusion injury
nd the processes of microvascular dysfunction and irrevers-
ble necrosis (12). This may also reflect the rapid time course
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1294s recanalized in the clinical setting, it is already too late to
nfluence many of the biochemical and cellular derange-
ents present in acute myocardial injury (13).
As PPCI has matured and become widely implemented,
he emphasis has somewhat shifted away from the nature of
he therapy toward enhancing the rapid delivery of care to
ll eligible patients. Recent data have demonstrated a
ratifying decline in the time from hospital presentation to
he onset of therapy. Unfortunately, however, little
rogress has been made in overcoming one of the major
urdles to early reperfusion—the time from symptom
nset to presentation (14).
For the present, there is need for a trial of pharmacolog-
cal recanalization as an adjunct to PCI in patients present-
ng early (1 to 2 h) in whom substantial delay (2 h) to
CI is anticipated, particularly in patients with large infarcts
r who are hemodynamically unstable (9). Nonetheless and
ealistically, the benefits of this approach will be limited as
ong as the time-to-presentation is in the range of 90 to 120
in for the majority. For decades, we have appreciated that
cute myocardial infarction is a time-critical phenomenon
nd that early therapy is crucial for myocardial recovery,
specially in the hyperacute phase, when “time is myocar-
ium.” Educating the public to seek treatment at an early
tage after symptom onset is likely to reduce mortality to a
reater degree than pharmacological facilitation before PCI,
lthough translation of this goal to reality in a community
etting is and will continue to be extremely difficult.
eprint requests and correspondence: Dr. Bernard J. Gersh,
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edicine, Mayo Clinic, 200 First Street, SW, Rochester, Minne-
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